Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2834942 | 0.85 | SLC6A2 (0.38) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2844273 | 0.84 | ALDH1A1 (0.31) | KMT2A | |
| SCHEMBL2835927 | 0.83 | IMPDH2 (0.38) | — | |
| Hydrochloric Acid SCHEMBL2837924 | 0.82 | KMT2A (0.36) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2841599 | 0.81 | SLC6A4 (0.32) | SLC6A4 | |
| SCHEMBL2840841 | 0.79 | MEN1 (0.37) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2846176 | 0.76 | MEN1 (0.38) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2839592 | 0.75 | SLC6A2 (0.34) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2839422 | 0.74 | MEN1 (0.39) | MEN1KMT2ATSHRL3MBTL1HRH3 | |
| SCHEMBL2838043 | 0.73 | SLC6A2 (0.35) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | MEN1 3895/4885KMT2A 1371/4885SLC6A2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.